Salud financiera de hoja de balance de Sensorion

Salud financiera controles de criterios 6/6

Sensorion tiene un patrimonio de los accionistas total de €83.5M y una deuda total de €1.6M, lo que sitúa su ratio deuda-patrimonio en 2%. Sus activos y pasivos totales son €101.5M y €18.1M respectivamente.

Información clave

2.0%

Ratio deuda-patrimonio

€1.65m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€87.34m
Patrimonio	€83.46m
Total pasivo	€18.07m
Activos totales	€101.53m

Actualizaciones recientes sobre salud financiera

Companies Like Sensorion (EPA:ALSEN) Are In A Position To Invest In Growth

Sep 26

Recent updates

Companies Like Sensorion (EPA:ALSEN) Are In A Position To Invest In Growth

Sep 26

Did The Underlying Business Drive Sensorion's (EPA:ALSEN) Lovely 310% Share Price Gain?

Mar 20

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€98.0M) de ALSEN superan a sus pasivos a corto plazo (€14.2M).

Pasivo a largo plazo: Los activos a corto plazo de ALSEN (€98.0M) superan a sus pasivos a largo plazo (€3.9M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ALSEN tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de ALSEN ha pasado de 922.3% a 2% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ALSEN tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: ALSEN dispone de suficiente cash runway para 1.8 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 16.7% cada año.

Salud financiera de hoja de balance de Sensorion

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Companies Like Sensorion (EPA:ALSEN) Are In A Position To Invest In Growth

Recent updates

Consensus revenue estimates increase by 13%

First half 2024 earnings released

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

New major risk - Revenue and earnings growth

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024

Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries

Consensus revenue estimates increase by 15%

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

New minor risk - Market cap size

Consensus revenue estimates increase by 242%

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Price target decreased by 14% to €2.33

Sensorion SA to Report Q2, 2023 Results on Sep 18, 2023

New major risk - Revenue and earnings growth

New major risk - Share price stability

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk

Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study

Price target decreased by 33% to €1.80

Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Less than half of directors are independent

Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Price target increased to €3.90

Companies Like Sensorion (EPA:ALSEN) Are In A Position To Invest In Growth

Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA to Report First Half, 2022 Results on Sep 22, 2022

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA, Annual General Meeting, May 31, 2022

Price target increased to €5.15

Price target decreased to €4.53

Less than half of directors are independent

Sensorion SA to Report Fiscal Year 2021 Results on Oct 31, 2022

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to €4.93

Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

First half 2021 earnings released

Sensorion Announces Regulators Approval for Sensorion’s Amendment to Phase 2 Audible-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Did The Underlying Business Drive Sensorion's (EPA:ALSEN) Lovely 310% Share Price Gain?

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

New 90-day high: €2.63

Sensorion Announces Third Gene Therapy Collaboration with Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

Sensorion Announces Preclinical Data Demonstrating SENS-401's Potential to Preserve Residual Hearing After Cochlear Implantation

New 90-day high: €1.66

Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss

Sensorion SA announced that it expects to receive €4.999999 million in funding from Sonova Holding AG

New 90-day low: €1.00

Sensorion and Novasep Announce Signature of A Gene Therapy Product Development and Manufacturing Agreement

Sensorion SA has completed a Follow-on Equity Offering in the amount of €31.0012 million.

New 90-day high - €2.19

New 90-day high - €1.65

Analysts update estimates

New 90-day high - €1.20

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera